(Q24239971)

https://api.crossref.org/works/10.1002%2F14651858.CD007655.PUB2

Clinical outcomes by race in hypertensive patients with and without the metabolic syndrome: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007655.PUB2

Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007655.PUB2

Mechanism of action of reserpine in producing gastric haemorrhage and erosion in the mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007655.PUB2

Step 2 regimens in hypertension. An assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007655.PUB2

Low-dose reserpine/thiazide combination in first-line treatment of hypertension: efficacy and safety compared to an ACE inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007655.PUB2

Mild hypertension: a clinical trial conducted in hospital general practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007655.PUB2

Systematic reviews in health care: Assessing the quality of controlled clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007655.PUB2

Antihypertensive Properties of Cryptenamine Used with Reserpine and Methyclothiazide

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007655.PUB2

Methodologic variation in case-control studies of reserpine and breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007655.PUB2

Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007655.PUB2

Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007655.PUB2

Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007655.PUB2

Risk factors for stroke and type of stroke in persons with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007655.PUB2

Diuretic-based treatment and cardiovascular events in patients with mild renal dysfunction enrolled in the systolic hypertension in the elderly program.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007655.PUB2

Influence of long-term, low-dose, diuretic-based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension: The Systolic Hypertension in the Elderly Program. SHEP Cooperat

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007655.PUB2

Long-term fatal outcomes in subjects with stroke or transient ischemic attack: fourteen-year follow-up of the systolic hypertension in the elderly program

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007655.PUB2

Treatment of hypertension in the elderly: I. Blood pressure and clinical changes. Results of a Department of Veterans Affairs Cooperative Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007655.PUB2

Hypertension treated with Rauwolfia serpentina (whole root) and with reserpine; controlled study disclosing occasional severe depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007655.PUB2

7 January 2021

First-line diuretics versus other classes of antihypertensive drugs for hypertension

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007655.PUB2

7 January 2021

Comparative evaluation of Rauwolfia whole root and reserpine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007655.PUB2

7 January 2021

The value of Rauwolfia serpentina in the hypertensive patient

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007655.PUB2

7 January 2021

Effects of treatment in hypertension. Results of a controlled study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007655.PUB2

7 January 2021

Hypotensive action of reserpin

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007655.PUB2

7 January 2021

The use of Rauwolfia serpentina in hypertensive patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007655.PUB2

7 January 2021

Technic of controlled drug assay illustrated by a comparative study of Rauwolfia serpentina, phenobarbital and placebo in the hypertensive patient

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007655.PUB2

7 January 2021

Effect of varying doses of reserpine on gastric secretion

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007655.PUB2

7 January 2021

Treatment of hypertension with oral reserpine alone and in combination with hydralazine or hexamethonium

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007655.PUB2

7 January 2021

Reserpine as an antihypertensive in the outpatient clinic; a double-blind clinical study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007655.PUB2

7 January 2021

The role of reserpine in essential hypertension when used alone or combined with hydralazine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007655.PUB2

7 January 2021

METHYLDOPA AND HYDROCHLOROTHIAZIDE COMPARED WITH RESERPINE AND HYDROCHLOROTHIAZIDE IN HYPERTENSION

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007655.PUB2

7 January 2021

Effect of Rauwolfia serpentina and reserpine on the blood pressure in essential hypertension; a long-term double-blind study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007655.PUB2

7 January 2021

Patient acceptance of guanethidine as therapy for mild to moderate hypertension. A comparison with reserpine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007655.PUB2

7 January 2021

Different concepts in first-line treatment of essential hypertension. Comparison of a low-dose reserpine-thiazide combination with nitrendipine monotherapy. German Reserpine in Hypertension Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007655.PUB2

7 January 2021

Treatment of hypertension with reserpine (serpasil) alone and in combination with hydralazine (apresoline)

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007655.PUB2

7 January 2021

The Systolic Hypertension in the Elderly Program (SHEP): an intervention trial on isolated systolic hypertension. SHEP Cooperative Research Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007655.PUB2

7 January 2021

10.1002/14651858.CD007655.PUB2

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

Consolidated OpenCitations Corpus – April 2017

PubMed publication ID

19821434

1 reference

Consolidated OpenCitations Corpus – April 2017